<p>Neutralization was shown as the percent inhibition of virus infection at 1∶20 dilution of the patient sera or using 10 µg/ml of monoclonal antibodies (b12, 2G12, and 4E10). “−“ indicates that percent of neutralization was below 50%. Percent of neutralization between 50–75% or greater than 75% are highlighted in yellow or red, respectively. The HIV-1 pseudotyped viruses used for neutralization assays are shown in the second row from top from “NL4-3” to “CM235.c11” with subtype indicated above the virus panel. “MuLV” is the murine leukemia virus used as negative control for neutralization assays. “NJ0XX”s in the far left column indicates individual patient serum samples; patient HIV subtypes are indicated above each group of samples. Known...
<p>Subtype A gp120 binding antibody titers correlate with the mean NAb titers against all 10 pseudov...
<p>The neutralization curves of anti-V3 mAb 2191 against nine selected HIV-1 pseudoviruses are shown...
<p><b><i>In vitro</i> neutralization data for individual antibodies against A, C & D subtype pseudov...
<p>Neutralization against pseudotyped viruses expressing primary Env from subtypes B, BC, C, and AE ...
The neutralization sensitivity of the contemporary, CCR5-utilizing, subtype B pseudoviruses (PSVs) w...
<p>Panels A, B, C and D represent the percent (%) of neutralization at 1∶20 serum dilution against t...
The neutralization phenotypes of HIV-1 mAbs and polyclonal mixtures from subjects VC10014 and VC2001...
<p>Shown is the breadth of neutralization for each serum sample against a panel of 10 pseudoviruses ...
<p>Sera from 50 HIV-1 subtype A-infected patients were tested in the TZM-bl neutralization assay aga...
Neutralizing antibodies (Nabs) are thought to play an important role in prevention and control of HI...
OBJECTIVE: Using clinical isolates from a recent passive immunization trial with antibody 2G12, we p...
The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In th...
AbstractNeutralizing antibodies (Nabs) are thought to play an important role in prevention and contr...
Identification of broadly neutralizing antibodies (NAbs) generated during the course of HIV-1 infect...
<p>The neutralization breadth of plasma antibodies from 6 plasma samples obtained from HIV-1 infecte...
<p>Subtype A gp120 binding antibody titers correlate with the mean NAb titers against all 10 pseudov...
<p>The neutralization curves of anti-V3 mAb 2191 against nine selected HIV-1 pseudoviruses are shown...
<p><b><i>In vitro</i> neutralization data for individual antibodies against A, C & D subtype pseudov...
<p>Neutralization against pseudotyped viruses expressing primary Env from subtypes B, BC, C, and AE ...
The neutralization sensitivity of the contemporary, CCR5-utilizing, subtype B pseudoviruses (PSVs) w...
<p>Panels A, B, C and D represent the percent (%) of neutralization at 1∶20 serum dilution against t...
The neutralization phenotypes of HIV-1 mAbs and polyclonal mixtures from subjects VC10014 and VC2001...
<p>Shown is the breadth of neutralization for each serum sample against a panel of 10 pseudoviruses ...
<p>Sera from 50 HIV-1 subtype A-infected patients were tested in the TZM-bl neutralization assay aga...
Neutralizing antibodies (Nabs) are thought to play an important role in prevention and control of HI...
OBJECTIVE: Using clinical isolates from a recent passive immunization trial with antibody 2G12, we p...
The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In th...
AbstractNeutralizing antibodies (Nabs) are thought to play an important role in prevention and contr...
Identification of broadly neutralizing antibodies (NAbs) generated during the course of HIV-1 infect...
<p>The neutralization breadth of plasma antibodies from 6 plasma samples obtained from HIV-1 infecte...
<p>Subtype A gp120 binding antibody titers correlate with the mean NAb titers against all 10 pseudov...
<p>The neutralization curves of anti-V3 mAb 2191 against nine selected HIV-1 pseudoviruses are shown...
<p><b><i>In vitro</i> neutralization data for individual antibodies against A, C & D subtype pseudov...